Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | TAS1R3 | Q7RTX0 | 3/20 | 0.40 |
| ▸ | TAS1R1 | Q7RTX1 | 3/20 | 0.40 |
| ▸ | ITGB3 | P05106 | 7/20 | 0.39 |
| ▸ | ITGA2B | P08514 | 6/20 | 0.39 |
| ▸ | ITGAV | P06756 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17009347 | 1.00 | POLB (0.46) | POLBHPGDTRPM8GAATAS1R3 | |
| SCHEMBL6127212 | 1.00 | POLB (0.46) | POLBHPGDTRPM8GAATAS1R3 | |
| SCHEMBL6127110 | 1.00 | POLB (0.46) | POLBHPGDTRPM8GAATAS1R3 | |
| SCHEMBL4698443 | 1.00 | POLB (0.46) | POLBHPGDTRPM8GAATAS1R3 | |
| SCHEMBL6122200 | 1.00 | POLB (0.46) | POLBHPGDTRPM8GAATAS1R3 | |
| SCHEMBL4700500 | 0.96 | POLB (0.43) | POLBHPGDTRPM8GAATAS1R3 | |
| SCHEMBL7900077 | 0.96 | HPGD (0.44) | POLBHPGDTRPM8GAATAS1R3 | |
| SCHEMBL24119265 | 0.95 | POLB (0.47) | POLBHPGDTRPM8GAATAS1R3 | |
| SCHEMBL7901816 | 0.93 | POLB (0.45) | POLBHPGDTRPM8GAATAS1R3 | |
| SCHEMBL4698454 | 0.93 | POLB (0.42) | POLBHPGDTRPM8GAATAS1R3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107820429-B | Novel compositions and methods for immunotherapy comprising small molecule integrin receptor-ligand agonist adjuvants | 7山药物有限责任公司 | 2022-08-16 | — | — | CN | disclosed |
| US-20210393811-A1 | Imaging Agents and Methods of Use | TEXAS HEART INSTITUTE | 2021-12-23 | — | — | US | disclosed |
| WO-2020072784-A1 | IMAGING AGENTS AND METHODS OF USE | TEXAS HEART INSTITUTE (US) | 2020-04-09 | — | — | WO | disclosed |
| EP-3388429-A1 | AGONISTS THAT ENHANCE BINDING OF INTEGRIN-EXPRESSING CELLS TO INTEGRIN RECEPTORS | Texas Heart Institute (US) | 2018-10-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210393811-A1 | Imaging Agents and Methods of Use | ITGA1, ITGA4, CD47 | POLB 4644/4885HPGD 4754/4885TRPM8 1025/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.